Related Experiment Videos
Clinical and hemodynamic results with the Carpentier-Edwards porcine bioprosthesis
Insights
The Carpentier-Edwards porcine valve shows good clinical improvement in 605 patients undergoing valve replacement. This bioprosthesis offers a low incidence of complications and tissue failure at five years.
Area of Science:
- Cardiovascular Surgery
- Biomaterials Science
Background:
- Heart valve replacement is a common procedure.
- Bioprosthetic valves offer an alternative to mechanical valves.
- Long-term outcomes of bioprosthetic valves are crucial for patient management.
Purpose of the Study:
- To evaluate the long-term clinical performance and safety of Carpentier-Edwards porcine bioprostheses.
- To assess survival rates, patient outcomes, and complication incidence after valve replacement.
Main Methods:
- Retrospective analysis of 605 patients who received Carpentier-Edwards bioprostheses.
- Follow-up data collected for up to 964 patient-years.
- Actuarial survival and complication rates calculated.
Main Results:
- Five-year actuarial survival rates were 87% (aortic), 83% (mitral), and 81% (multiple valve replacement).
- 68% of survivors remained asymptomatic, and 18% improved.
- Incidence rates per patient-year: thromboembolism 2.0%, endocarditis 1.3%, reoperation 0.1%.
Conclusions:
- Carpentier-Edwards porcine valves demonstrate good clinical improvement and satisfactory hemodynamic performance.
- The bioprosthesis exhibits a low incidence of valve-related complications and tissue failure at five years.
- These findings support the use of Carpentier-Edwards porcine valves in clinical practice.
Abstract:
Carpentier-Edwards bioprostheses were implanted in 605 patients, 509 of whom had a single valve replacement, and 96 of whom had a multiple valve replacement. There were 54 early deaths (8.9%) and 26 late deaths (4.3%). The five-year actuarial survival was 87% for aortic valve replacement, 83% for mitral valve replacement, and 81% for multiple valve replacement. Of the 525 survivors, all but 3 were followed for a total of 964 patient-years; 354 patients (68%) remained asymptomatic, and 95 patients (18%) were improved. The incidence of thromboembolism, endocarditis, and reoperation due to primary tissue failure of the bioprosthesis were 2.0, 1.3, and 0.1% per patient-year, respectively. The actuarial probability of being free of all valve-related complications was 93% after five years. Satisfactory hemodynamic performance of the bioprosthesis was demonstrated by postoperative studies done in 70 patients. Thus, the Carpentier-Edwards porcine valve provides good clinical improvement, with a low incidence of valve-related complications and tissue failure at five years postoperatively.